Tag Archives: ASCO

Reiterate Caution on Biopharmaceutical Stocks With Major 3% Sector Sell-Off

Raise More Cash- No Change in Rayno Biopharma Portfolio Last month we raised the yellow flag on the biotech sector because of a choppy tape, new highs with weakness in MO (Momentum) plays and the anticipation of ASCO news that could trigger a “sell on the news” trend. Moreover CNBC pundits have been pushing biotech [...]

Comments Off Continue Reading →

Reversal Day-Caution is Back-NASDAQ Down 1% or 35Pts– Update 5/23

Biotechs Bounce Back After Deep Dive Unless you were trading at the open today and covered your shorts you could have been whipsawed in a volatile market that had NASDAQ down to the 3425 level. Many biotech stocks recovered today so no technical damage. The IBB was down 5% low to high over two days [...]

Comments Off Continue Reading →

Rayno Life Science: Bringing on the Green After a Four Day Rest

Biopharmaceutical Stocks Rally- Many Rayno Picks up 2%+ If the past four days was the long awaited biotechnology correction it was barely noticeable, a mere 3.7% high to low over the past week.Today the rally has resumed with major large cap holdings from funds and ETFs for example : ALXN, AMGN, BIIB, GILD, and PCYC. [...]

Comments Off Continue Reading →

Oncology Pipeline Analysis from Linda Pullan: ASCO Primer

ASCO Meeting Coming Up May 31 With the ASCO Meeting coming up at the end of the month, we are pleased to provide oncology pipeline data from Linda Pullan. There was a lot of interest on this WEB site when we provided data in June 2010. The link is Pullan’s Pieces #81 April 2013. Her recent [...]

Comments Off Continue Reading →

Very Limited ASCO Boost For Biotechnology Stocks – Update 1 PCYC

A Biopharma Stock We Missed-Pharmacyclics (PCYC $38.21) up 9.89% today It is unbelievable that we missed the huge move in PCYC up 157% YTD with a one year range of 7.63 to 38.56. The market cap is $2.63B. The Company has a robust pipeline of products led by Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor [...]

Comments Off Continue Reading →

Stocks to Watch: ASCO -continued-INCY, ONXX, SUPG

This is a continuation of pre-ASCO coverage, reviewing companies that will have significant clinical presentations on cancer products in their pipeline. Incyte Corporation (INCY $17.82) up 1.94%. is focused on small molecule drugs for hematological and oncology applications and for chronic autoimmune and inflammatory diseases.In oncology the Company has four indications for its JAK inhibitor [...]

Comments Off Continue Reading →